Adoptive cell therapy for the treatment of patients with metastatic melanoma. - Wikidata - awgldk - TriplyDB

Adoptive cell therapy for the treatment of patients with metastatic melanoma.

Adoptive cell therapy for the treatment of patients with metastatic melanoma.

http://www.wikidata.org/entity/Q36283034

about

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma Eradication of melanomas by targeted elimination of a minor subset of tumor cells Involvement of ABC transporters in melanogenesis and the development of multidrug resistance of melanoma Dendritic Polymers for Theranostics Effects of Alcohol on Tumor Growth, Metastasis, Immune Response, and Host Survival Adoptive T-Cell Immunotherapy Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook Innate and adaptive immune cells in the tumor microenvironment Clinical application of adoptive T cell therapy in solid tumors Tumor infiltrating lymphocytes in ovarian cancer Current translational and clinical practices in hematopoietic cell and gene therapy Ultrasound-mediated targeted drug delivery: recent success and remaining challenges Cancer immunotherapy TCRs Used in Cancer Gene Therapy Cross-React with MART-1/Melan-A Tumor Antigens via Distinct Mechanisms Peptide length determines the outcome of TCR/peptide-MHCI engagement Targeted immune therapy of ovarian cancer Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1 PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome.Dendritic cells transfected with Her2 antigen-encoding RNA replicons cross-prime CD8 T cells and protect mice against tumor challenge.MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia.Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine Interface of signal transduction inhibition and immunotherapy in melanoma.Immunotherapy for recurrent ovarian cancer: a further piece of the puzzle or a striking strategy?T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies.Tumor immunity against a simian virus 40 oncoprotein requires CD8+ T lymphocytes in the effector immune phase Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice.What's the place of immunotherapy in malignant mesothelioma treatments?High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells Melanoma: a model for testing new agents in combination therapies.CD4+ T cells elicit host immune responses to MHC class II-negative ovarian cancer through CCL5 secretion and CD40-mediated licensing of dendritic cells.Differences in TCR-Vβ repertoire and effector phenotype between tumor infiltrating lymphocytes and peripheral blood lymphocytes increase with age.Chronic alcohol consumption enhances myeloid-derived suppressor cells in B16BL6 melanoma-bearing mice.BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice Whole-body irradiation increases the magnitude and persistence of adoptively transferred T cells associated with tumor regression in a mouse model of prostate cancer Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer.CAR-modified T-cell therapy for cancer: an updated review.Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor Ex vivo expansion of human CD8+ T cells using autologous CD4+ T cell help Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection.

P2860

Q24602657-BFC9C3C2-B0C3-4B04-8CE1-203B4279A4F4 Q24624761-54389066-C50C-4D3B-ACEA-78A201C83C94 Q24649754-0FFF66CE-8BBA-4BFC-A6C1-8B7D11E6085C Q26746182-1199A8E6-3878-4AFA-A9DC-C1695228E1F7 Q26773212-AFA1614E-433A-42C2-8E99-2E4654055901 Q26782845-324B0C54-2E13-44A1-8A81-E5BD5DBD91B1 Q27004178-FFB608B3-1272-408C-9E07-9EC8AF174AA8 Q27008342-B5153784-DBD7-4A90-BD2D-9D3ADEF6D9E1 Q27011283-136C950B-DC50-40A0-AEC8-DC44C5AB45C4 Q27021878-4DB8DC02-168C-4FC2-9046-25ED6B9CED5D Q27024456-B3FF38AF-E2F5-4558-90C4-A5CEF0E0F208 Q27026689-B2716060-11D4-484D-B99C-C00521C2137E Q27026870-4A854063-26E7-4C36-B355-76AA8755B104 Q27671024-2771159D-A5BD-49A8-93B8-5C6EF09F80A2 Q27675544-EBC1D921-8752-4430-9894-881A309060CB Q28082828-1791A820-5436-4F35-A168-482836BE737A Q29616128-DEC348EA-3EA4-4238-AEF3-DADDACF72169 Q30275174-B64D6E27-7456-46A8-BC4B-6CF94EC6EAC2 Q30318566-CB59A25A-BF85-44CA-A194-78659E7C7D0F Q30412320-D08164EE-4EB6-42BE-A83D-767ED8CBB273 Q30422102-ECF8658C-28AD-47B7-A1DE-B85D5E4CDDBB Q30425914-32A9B6DC-B7A2-4397-938D-56F98A73609E Q30429380-E403E849-C34F-4E3E-9017-647FD0A0D168 Q33357295-5DFE63A9-3E2D-40EB-B635-D5F37BA14EAF Q33530527-051B0B43-A6D2-430F-A0CE-C100E6AF68C3 Q33558482-D496F335-F5BF-41FA-925F-446174929E25 Q33560416-05C52B68-5376-4714-92E0-36E91018C97D Q33781142-FDC8080C-60B1-46FD-A0B2-9524C38FD19A Q33806895-6EB9E4B8-CE98-48E3-A13B-8810E17FAA10 Q33863916-062F1250-EAD3-40A1-B56A-8F172B32AE24 Q33867018-8313E296-F989-4A97-93DB-F9693624357F Q33895977-869B7DF0-3EE0-4885-8294-C893918430D7 Q33898612-315FF4E1-CAD7-4636-BF7E-A8198E306D1E Q33996674-DC35BE56-3DB5-4D89-9126-6C144C5D98C8 Q34016750-F21D8306-2977-428C-9C2D-09ED67D648A6 Q34031748-6DBCCEA5-65B4-4B16-B307-F3C4AAF441BD Q34044213-1BE23A1B-92AA-48DE-AEA6-165ED55785E1 Q34046489-DE27F4BA-82DB-4EF9-A125-4B1495687AE8 Q34141754-4A1FDB54-CF1C-4B40-9ABD-B0A4C952AFC9 Q34166288-032E50D4-7786-4A1D-B189-78229406FCBB

P2860

Adoptive cell therapy for the treatment of patients with metastatic melanoma.

http://www.wikidata.org/entity/Q36283034

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Adoptive cell therapy for the treatment of patients with metastatic melanoma.

@ast

Adoptive cell therapy for the treatment of patients with metastatic melanoma.

@en

type

label

Adoptive cell therapy for the treatment of patients with metastatic melanoma.

@ast

Adoptive cell therapy for the treatment of patients with metastatic melanoma.

@en

prefLabel

Adoptive cell therapy for the treatment of patients with metastatic melanoma.

@ast

Adoptive cell therapy for the treatment of patients with metastatic melanoma.

@en

P1433

Q36283034-E6A3982D-2896-40C2-8A40-1FA280FF58C7

P1476

Q36283034-39C2E344-DAD5-4178-BCF9-3668FCE157FC

P2093

Q36283034-1D64DD3F-887C-467B-AE80-63D6A798CC25

Q36283034-836D8715-E6DC-4912-9D23-B7930C9B667F

P2860

Q36283034-009CB84D-5B13-499A-87C7-F1C0D17BC2D0

Q36283034-1D90D776-C946-4C5D-925F-79FE8B6124E3

Q36283034-20475F7F-3DF8-4A71-AC9D-246BACFF19A8

Q36283034-2D4E5CB2-BD0A-4AF0-B1C8-38C404DA20AC

Q36283034-34982074-482E-428F-A509-2B548B901B21

Q36283034-46F8001A-9B75-4D54-A933-4460F241B827

Q36283034-48759717-E1E2-42AB-A6B6-FFFFC640A7C9

Q36283034-52067507-BE15-4A39-BAF5-0DCDEBD45BB1

Q36283034-5600059C-15BD-4D64-A570-A9CE801FE1CF

Q36283034-5CA170BD-AA14-4E15-BC8C-64D05527E771

P304

Q36283034-FBF8D18B-3F4F-4FE0-9236-BFD9228D60BB

P31

Q36283034-CC632753-0FC2-4D13-8460-C4DED5A9D6E3

P356

Q36283034-361EA28E-5885-4D06-94C7-5AAF56791131

P433

Q36283034-8C07F3B8-FB4E-4A6F-B264-4913B68DA4A4

P478

Q36283034-2D4F7586-0BB9-4AE9-BF51-35460039DDC5

P577

Q36283034-C87A98D3-3A75-4ADD-BFDD-EC35996D88FD

P5875

Q36283034-100206A7-5868-4FE6-89FD-03E5E4A36B4A

P698

Q36283034-0233F504-19CF-4957-9FB8-CABCC97B978B

P921

Q36283034-3298FE27-5C1E-4FD8-B209-616929B9E7E3

P932

Q36283034-2F7931E4-95AF-4DA5-9561-359D9E56E24A

P356

J.COI.2009.03.002

P1433

Current Opinion in Immunology

P1476

Adoptive cell therapy for the treatment of patients with metastatic melanoma.

@en

P2093

Mark E Dudley

http://www.w3.org/2001/XMLSchema#string

Steven A Rosenberg

http://www.w3.org/2001/XMLSchema#string

P2860

A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma

Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

Cancer immunotherapy: moving beyond current vaccines

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

Cancer regression in patients after transfer of genetically engineered lymphocytes

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

P304

233-240

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.COI.2009.03.002

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2009-03-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24217902

http://www.w3.org/2001/XMLSchema#string

P698

19304471

http://www.w3.org/2001/XMLSchema#string

P921

P932

3459355

http://www.w3.org/2001/XMLSchema#string